Summary of Key Points Core Viewpoint - Tianyuan Medical (00557.HK) anticipates a significant decline in total revenue for the six months ending June 30, 2025, projecting approximately HKD 8.4 million, a decrease of about 44% compared to approximately HKD 14.9 million for the previous period [1][3]. Revenue Decline Reasons - The primary reason for the expected revenue decrease is the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group. This is expected to result in a revenue drop of no less than approximately HKD 6.2 million, reducing medical business revenue to about HKD 0.5 million (previous period: approximately HKD 6.7 million) [3]. Net Loss Projection - The company projects a net loss of approximately HKD 8.4 million for the interim period, compared to a net loss of approximately HKD 9 million for the previous period. This anticipated loss is primarily attributed to the estimated decrease in total revenue, offset by a corresponding reduction in operating costs [3]. Business Overview - Tianyuan Medical's main business activities include investment holding, providing procurement, marketing, management, franchising, and plastic surgery services to the medical industry, as well as lending and related services, and offering procurement services to the hotel industry [3].

Core Viewpoint - Tianyuan Medical (00557.HK) anticipates a total revenue of approximately HKD 8.4 million in the first half of 2025, representing a year-on-year decrease of about 44% [1] Group 1 - The expected decline in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital Co., Ltd., in which the group holds partial interests [1] - The medical business revenue is projected to decrease by no less than approximately HKD 6.2 million, down to about HKD 0.5 million, compared to approximately HKD 6.7 million in the previous period [1]

Group 1 - The company, Tianyuan Medical (00557), expects total revenue of approximately HKD 8.4 million in the first half of 2025, representing a year-on-year decrease of about 44% [1] - The anticipated revenue decline is primarily due to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue decrease of no less than HKD 6.2 million to approximately HKD 0.5 million (previous period: approximately HKD 6.7 million) [1] - The company expects a net loss of approximately HKD 8.4 million for the interim period, compared to a net loss of approximately HKD 9 million in the previous period, with the estimated net loss mainly attributed to the decrease in total revenue [1]

Core Viewpoint - Tianyuan Medical (00557) anticipates a significant decline in total revenue for the first half of 2025, projecting approximately HKD 8.4 million, a year-on-year decrease of about 44% [1] Revenue Forecast - The expected decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of at least HKD 6.2 million to around HKD 0.5 million (previous period: approximately HKD 6.7 million) [1] Net Loss Projection - The group expects to incur a net loss of approximately HKD 8.4 million during the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated reduction in total revenue compared to the previous period, offset by a corresponding decrease in operating costs [1]

Core Viewpoint - Tianyuan Medical (00557.HK) expects total revenue for the six months ending June 30, 2025, to be approximately HKD 8.4 million, a decrease of about 44% compared to approximately HKD 14.9 million in the previous period [1] Revenue Summary - The anticipated decrease in total revenue is primarily attributed to the suspension of operations and renovations at Shanghai Yuyue Weilai Medical Beauty Hospital, which is partially owned by the group, leading to a projected revenue drop of no less than approximately HKD 6.2 million to about HKD 500,000 (previous period: approximately HKD 6.7 million) [1] Net Loss Summary - The group expects to record a net loss of approximately HKD 8.4 million for the interim period (previous period: approximately HKD 9 million) [1] - The estimated net loss is mainly due to the anticipated decrease in total revenue, offset by a corresponding reduction in operating costs [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公佈全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 盈利警告公佈 本公佈乃由中國天元醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集 團」）董事（「董事」）會（「董事會」）根據香港聯合交易所有限公司證券上市規則 （「上市規則」）第13.09(2)(a)條及香港法例第571章證券及期貨條例第XIVA部項 下的內幕消息條文（定義見上市規則）而作出。 董事會謹此知會本公司股東（「股東」）及潛在投資者，根據對本集團最近期未經 審核綜合管理賬目的初步評估及本公司目前可獲得的資料，預期本集團於截至 二零二五年六月三十日止六個月（「中期期間」）將錄得總收益約8,400,000港元， 較截至二零二四年六月三十日止六個月（「前一期間」）的約14,900,000港元減少 約44%。預期總收益減少乃主要歸因於上海愉悅薇萊醫療美容醫院有限公司（本 集團擁有部分權益及位於中華人民共和國上海市的 ...

Core Viewpoint - Tianyuan Medical (00557.HK) will hold a board meeting on August 29, 2025, to review and approve the interim results for the six months ending June 30, 2025, and to consider the proposal for an interim dividend distribution, if any [1] Summary by Categories - Company Announcement - The board meeting is scheduled for August 29, 2025 [1] - The meeting will focus on the interim results for the six months ending June 30, 2025 [1] - The board will also consider the proposal for an interim dividend distribution [1]

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因 依賴該等內容而引致之任何損失承擔任何責任。 承董事會命 中國天元醫療集團有限公司 執行董事 東薇 香港，二零二五年八月十四日 於本公告日期，本公司董事會由五名董事組成，其中東薇女士為執行董事；賀梅女士為非執 行董事；及阮國權先生、周思奇女士及李軍先生為獨立非執行董事。 董事會會議通告 中國天元醫療集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 （「董事」）會（「董事會」）謹此宣佈，本公司董事會將於二零二五年八月二十九日 （星期五）下午四時舉行會議，藉以（其中包括）審議及批准本集團截至二零二五 年六月三十日止六個月之未經審核中期業績及其刊發，以及考慮派發中期股息 （如有）。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國天元醫療集團有限公司 呈交日期: 2025年8月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00557 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,720,615,042 | HKD | | | 1 HKD | | 2,720,615,042 | 本月底法定/註冊 ...

Core Viewpoint - Tianyuan Medical (00557) announced a capital increase agreement involving its indirect subsidiaries, which aims to enhance the operational capacity of Shanghai Rifu and strengthen the group's competitiveness in the medical services sector in China [1][3]. Group 1: Capital Increase Agreement - Hengqin Hanyue Mei will increase its investment in Shanghai Rifu by RMB 15.5152 million (approximately HKD 16.9116 million) through the conversion of debt into equity [1]. - Shanghai Huaman will contribute an additional RMB 10 million (approximately HKD 10.9 million) in cash to Shanghai Rifu [1]. - Following the capital increase, Shanghai Rifu's registered capital will rise from RMB 2.3846 million to RMB 27.8998 million, while the shareholding ratios of Hengqin Hanyue Mei and Shanghai Huaman will remain unchanged at 60.8077% and 39.1923%, respectively [1]. Group 2: Shareholder Loan Agreement - On July 21, 2025, Shanghai Huaman will provide a shareholder loan of RMB 3 million (approximately HKD 3.27 million) to Shanghai Rifu, with a loan term of 36 months [1]. Group 3: Strategic Collaboration - The capital increase and shareholder loan are designed to meet the operational funding needs of Shanghai Rifu, thereby providing additional working capital for its daily operations [3]. - The collaboration with Shanghai Huaman, a marketing company in the medical beauty sector, is expected to enhance the group's strategic value and create potential cooperation opportunities with other medical beauty centers in China [3]. - This partnership is anticipated to bring further support and resources to Shanghai Rifu and the overall group, driving growth momentum [3].